Jump to main content
Jump to site search

Issue 37, 2017
Previous Article Next Article

Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy

Author affiliations

Abstract

Since its initial identification, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been shown to be capable of selectively inducing apoptosis in cancer cells. However, translation of the encouraging preclinical studies of this cytokine into the clinic has been restricted by its extremely short half-life, the presence of resistant cancer cell populations, and its inefficient in vivo delivery. Recently, there has been exceptional progress in developing novel formulations to increase the circulatory half-life of TRAIL and new combinations to treat cancers that are resistant to TRAIL. In particular, TRAIL-based nanotherapies offer the potential to improve the stability of TRAIL and prolong its half-life in plasma, to specifically deliver TRAIL to a particular target site, and to overcome resistance to TRAIL. The aim of this review is to provide an overview of the state-of-the art drug delivery systems that are currently being tested or developed to improve the biological attributes of TRAIL-based therapies.

Graphical abstract: Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy

Back to tab navigation

Publication details

The article was received on 09 Jul 2017, accepted on 06 Sep 2017 and first published on 06 Sep 2017


Article type: Review Article
DOI: 10.1039/C7NR04959E
Citation: Nanoscale, 2017,9, 13879-13904
  •   Request permissions

    Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy

    X. Wu, S. Wang, M. Li, A. Wang, Y. Zhou, P. Li and Y. Wang, Nanoscale, 2017, 9, 13879
    DOI: 10.1039/C7NR04959E

Search articles by author

Spotlight

Advertisements